Lilly Set to Unveil More Than 50 Studies at...( INDIANAPOLIS May 12 /- Eli Lilly and ...)

INDIANAPOLIS, May 12 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) will unveil data from more than 50 studies at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla. from May 29 to June 2, 2009, with the majority of the presentations continuing to support Lilly's leadership in thoracic cancer research. The company will present the latest research findings on ALIMTA(R) (pemetrexed for injection), as well as GEMZAR(R) (gemcitabine HCl for injection), and enzastaurin, an investigational, oral, targeted therapy.

This year's ASCO also marks the first time Lilly will feature the newest molecules in its portfolio resulting from Lilly's recent acquisition of ImClone Systems.

"ASCO's theme of 'Personalizing Cancer Care' is one to which Lilly has subscribed for many years," said Richard Gaynor, M.D., Lilly vice president, cancer research and global oncology platform leader. "We are focused on delivering what we call 'tailored therapies' - an essential component of personalized medicine - to identify patients who are most likely to respond to therapy, and just as importantly, which patients will not.

"With ASCO studies focusing on non-small cell lung cancer, breast cancer, cervical cancer and biliary tract cancer, among others, Lilly will demonstrate its continued commitment to meeting the needs of patients across a broad oncology spectrum."

Studies of note for ALIMTA include:

• Abstract #CRA8000: Oral Presentation: May 31, 2009, 9:00 a.m.
  • Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer
  • This study is being presented at the ASCO press briefing on May 30, 11:0
    '/>"/>
  
  

  SOURCE Eli Lilly and Company Copyright©2009 PR Newswire. All rights reserved

  0 GOOD

  
  Page: 1 2 3 4 5 6
  Related biology technology :
  
  1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
  2. Lilly Declares Fourth-Quarter Dividend
  3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
  4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
  5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
  6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
  7. Lilly Announces Termination of AIR Insulin Program
  8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
  9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
  10. Lilly Reports Solid First-Quarter Results
  11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs